New hope for tough cancers: early trial tests novel therapy
NCT ID NCT06840821
Summary
This study is testing a new drug called MB0151 in adults with advanced solid tumors that have progressed after standard treatments. The main goals are to find a safe dose and see if the drug can shrink or control tumors. The trial is open to people with specific cancers, including certain neuroendocrine tumors, small cell lung cancer, and triple-negative breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.